Conference report: Sarah goes oligotherapeutics!
RNAmed PhD student attended the 19th annual meeting of the Oligonucleotide Therapeutics Society
“I had the opportunity to attend the 19th annual meeting of the Oligonucleotide Therapeutics Society (OTS), which was held October 22-25 in Barcelona, Spain.
I was fascinated by the broad spectrum of therapeutics covered at the conference, including microRNAs, CRISPR, RNAi and antisense technologies. It was super exciting to listen to talks by great pioneers of the field, such as David Liu, who presented his groundbreaking work in base and prime editing, and Sudhir Agrawal, who pioneered the chemistry of antisense oligonucleotides to provide them with drug-like properties.
Not only academia, but also the pharmaceutical industry was well represented. Thus, I was able to gain insights into some of the latest clinical research in the field, for instance, from a biotech company that presented data on its antisense technology to combat Duchenne Muscular Dystrophy (DMD), a genetic disease leading to muscle dystrophy and early death.
All in all, highly interesting talks, amazing people, and a beautiful venue—I am already looking forward to the next OTS meeting!” — Sarah Nentwich, RNAmed PhD student in the Vogel lab (Würzburg)
